Article

Economic evaluation of vaccination: Capturing the full benefits, with an application to human papillomavirus

Department of Global Health and Population, Harvard School of Public Health, Boston, MA, USA  Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa.
Clinical Microbiology and Infection (Impact Factor: 5.77). 07/2012; 18 Suppl 5(s5):70-6. DOI: 10.1111/j.1469-0691.2012.03977.x
Source: PubMed

ABSTRACT

Clin Microbiol Infect 2012; 18 (Suppl. 5): 70–76
Vaccination has been among the greatest contributors to the past century’s dramatic improvements in health and life expectancy. Recent advances in vaccinology have resulted in new vaccines that will likely lead to substantial future health gains. However, the high cost of these new vaccines, such as the human papillomavirus (HPV) vaccine, poses an obstacle to their widespread adoption in many countries. Economic evaluation can help to determine if investment in vaccine introduction is worthwhile. However, existing economic evaluations usually focus on a narrow set of vaccination-mediated benefits—most notably avoided medical-care costs—and fail to account for several categories of potentially important gains. We consider three sources of such benefit and discuss them with respect to HPV vaccination: (i) outcome-related productivity gains, (ii) behaviour-related productivity gains, and (iii) externalities. We also highlight that HPV vaccination protects against more than just cervical cancer and that these other health gains should be taken into account. Failing to account for these broader benefits of HPV vaccination could result in substantial underestimation of the value of HPV vaccination, thereby leading to ill-founded decisions regarding its introduction into national immunization programmes.

Full-text preview

Available from: onlinelibrary.wiley.com
  • Source
    • "Household costs do not include either the direct or ICs associated with sequelae, which affect 9.5% of survivors [27], and may be severe and costly [13, 28] . Moreover , recent experimental economic studies propose widening the scope of ICs by also including monetary estimates of interruptions in education schooling and the impact on cognitive de- velopment212223. Last, the focus here is on the economic impact on households and costs and savings for the health system . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Five years since the successful introduction of MenAfriVac in a mass vaccination campaign targeting 1- to 29-year-olds in Burkina Faso, consideration must be given to the optimal strategies for sustaining population protection. This study aims to estimate the economic impact of a range of vaccination strategies in Burkina Faso. Methods. We performed a cost-of-illness study, comparing different vaccination scenarios in terms of costs to both households and health systems over a 26-year time horizon. These scenarios are (1) reactive vaccination campaign (baseline comparator); (2) preventive vaccination campaign; (3) routine immunization at 9 months; and (4) a combination of routine and an initial catchup campaign of children under 5. Costs were estimated from a literature review, which included unpublished programmatic documents and peer-reviewed publications. The future disease burden for each vaccination strategy was predicted using a dynamic transmission model of group A Neisseria meningitidis. Results. From 2010 to 2014, the total costs associated with the preventive campaign targeting 1- to 29-year-olds with MenAfriVac were similar to the estimated costs of the reactive vaccination strategy (approximately 10 million US dollars [USD]). Between 2015 and 2035, routine immunization with or without a catch-up campaign of 1- to 4-year-olds is cost saving compared with the reactive strategy, both with and without discounting costs and cases. Most of the savings are accrued from lower costs of case management and household costs resulting from a lower burden of disease. After the initial investment in the preventive strategy, 1 USD invested in the routine strategy saves an additional 1.3 USD compared to the reactive strategy. Conclusions. Prevention strategies using MenAfriVac will be significantly cost saving in Burkina Faso, both for the health system and for households, compared with the reactive strategy. This will protect households from catastrophic expenditures and increase the development capacity of the population.
    Full-text · Article · Nov 2015 · Clinical Infectious Diseases
  • [Show abstract] [Hide abstract]
    ABSTRACT: Performing a total health economic analysis of a vaccine newly introduced into the market today is a challenge when using the conventional cost-effectiveness analysis we normally apply on pharmaceutical products. There are many reasons for that, such as: the uncertainty in the total benefit (direct and indirect) to be measured in a population when using a cohort model; (1) appropriate rules about discounting the long-term impact of vaccines are absent jeopardizing therefore their value at the initial investment; (2) the presence of opposite contexts when introducing the vaccine in developed vs. the developing world with high benefits, low initial health care investment for the latter vs. marginal benefit and high cost for the former; with a corresponding paradox for the vaccine becoming very cost-effective in low income countries but rather medium in middle low to high middle income countries; (3) and the type of trial assessment for the newer vaccines is now often performed with immunogenicity reaction instead of clinical endpoints which still leaves questions on their real impact and their head-to-head comparison. (4.)
    No preview · Article · Jan 2013 · Human Vaccines & Immunotherapeutics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Low-income rural Indians have poor access to nearby health-care services, preventive products, and insurance. These factors motivated this intervention wherein a composite health-care package was delivered by a telemedicine-enabled community health worker (CHW)—an important actor in the Indian health system given the shortage of doctors. Few studies that evaluate composite programmes of this type exist. Much of the research to date has been evaluations of health insurance, largely using quasi-experimental approaches on inpatient (or composite inpatient and outpatient cover) products with mixed findings. The CARE Foundation created a programme that offered an opportunity to assess, in an experimental setting, incentives to promote primary and preventive care and their likely follow-on effects on hospitalisation/serious illness episodes against alternative approaches that do not do so. This study expands the economic literature base to include research on the impact of outpatient insurance in a developing country using a randomised controlled trial (RCT) and to draw a link to hospitalisation.
    Full-text · Article · Jun 2013 · The Lancet
Show more